Astria Therapeutics (ATXS) Stock Price, News & Analysis

Company Overview

Astria Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for endocrine and autoimmune disorders. The company’s research portfolio includes long-acting hormone replacement products, enzyme replacement therapies, and targeted biologics designed to address chronic conditions such as adrenal insufficiency, hypoparathyroidism, and rare autoimmune indications. By leveraging proprietary formulation and delivery platforms, Astria aims to improve patient adherence and therapeutic outcomes compared to existing standards of care.

Since its founding in 2010 and public listing on the NASDAQ under the ticker ATXS, Astria has advanced multiple product candidates through preclinical and clinical development. Its lead program, a long-acting adrenocorticotropic hormone analog, recently entered pivotal clinical trials following encouraging Phase 2 results that demonstrated prolonged efficacy and a favorable safety profile. Additional pipeline assets include next-generation parathyroid hormone analogs and enzyme therapies engineered for reduced immunogenicity and enhanced tissue targeting.

Headquartered in Boston, Massachusetts, Astria operates a research and development hub in the U.S. and maintains strategic partnerships in Europe and Asia to facilitate global clinical studies and future market access. The company’s leadership team is spearheaded by CEO Dr. Elaine Marshall, a veteran biopharma executive with more than 25 years of experience in product development and regulatory affairs. Astria’s scientific advisory board brings together endocrinologists, immunologists, and pharmacokinetic experts to guide its translational research efforts and drive toward commercialization.

Key Stats

• Today's Range: $6.23 to $6.49
• 50-Day Range: $3.90 to $6.77
• 52-Week Range: $3.56 to $12.92
• Volume: 41,962 shs
• Average Volume: 354,960 shs
• Market Capitalization: $352.41 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $30.00
• Consensus Rating: Buy

Astria Therapeutics Stock Analysis - MarketRank™

Astria Therapeutics scored higher than 32% of companies evaluated by MarketBeat, and ranked 771st out of 937 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Buy

Consensus Rating

Astria Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.25, and is based on 6 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Astria Therapeutics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Astria Therapeutics are expected to decrease in the coming year, from ($1.65) to ($1.78) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Astria Therapeutics is -3.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Astria Therapeutics is -3.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Astria Therapeutics has a P/B Ratio of 1.60. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

7.00% of the float of Astria Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Astria Therapeutics has a short interest ratio ("days to cover") of 6.4.

Change versus previous month

Short interest in Astria Therapeutics has recently increased by 1.59%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Astria Therapeutics does not currently pay a dividend.

Dividend Growth

Astria Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

7.00% of the float of Astria Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Astria Therapeutics has a short interest ratio ("days to cover") of 6.4.

Change versus previous month

Short interest in Astria Therapeutics has recently increased by 1.59%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 1.6 / 5
• News Sentiment: N/A

News Sentiment

Astria Therapeutics has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Astria Therapeutics this week, compared to 3 articles on an average week.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Astria Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 4.50% of the stock of Astria Therapeutics is held by insiders.

Percentage Held by Institutions

98.98% of the stock of Astria Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ATXS Stock Analysis - Frequently Asked Questions

How have ATXS shares performed this year?

Astria Therapeutics' stock was trading at $8.94 at the beginning of 2025. Since then, ATXS stock has decreased by 28.9% and is now trading at $6.3520.

How were Astria Therapeutics' earnings last quarter?

Astria Therapeutics, Inc. (NASDAQ:ATXS) issued its earnings results on Tuesday, May, 13th. The biotechnology company reported ($0.58) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.48) by $0.10.

When did Astria Therapeutics' stock split?

Astria Therapeutics's stock reverse split on the morning of Friday, August 20th 2021.The 1-6 reverse split was announced on Friday, August 20th 2021. The number of shares owned by shareholders was adjusted after the closing bell on Friday, August 20th 2021. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split.

Who are Astria Therapeutics' major shareholders?

Astria Therapeutics' top institutional shareholders include Farther Finance Advisors LLC (0.01%). Insiders that own company stock include Perceptive Advisors Llc and Christopher Morabito.
View institutional ownership trends.

How do I buy shares of Astria Therapeutics?

Shares of ATXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Astria Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Astria Therapeutics investors own include CRISPR Therapeutics (CRSP), Voyager Therapeutics (VYGR), Waste Connections (WCN), American Water Works (AWK), DiamondRock Hospitality (DRH), The RMR Group (RMR) and AU Optronics (AUOTY).

Company Calendar

• Last Earnings: 5/13/2025
• Today: 7/17/2025
• Next Earnings (Estimated): 8/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ATXS
• CIK: 1454789
• Web: www.catabasis.com
• Phone: (617) 349-1971
• Fax: 617-273-2637
• Employees: 30
• Year Founded: 2008

Price Target and Rating

• Average Price Target for Astria Therapeutics: $30.00
• High Price Target: $47.00
• Low Price Target: $16.00
• Potential Upside/Downside: +373.2%
• Consensus Rating: Buy
• Rating Score (0-4): 3.25
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.87)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$94.26 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -47.18%
• Return on Assets: -31.26%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 17.39
• Quick Ratio: 17.39

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.97 per share
• Price / Book: 1.60

Miscellaneous

• Outstanding Shares: 56,430,000
• Free Float: 53,894,000
• Market Cap: $357.77 million
• Optionable: Optionable
• Beta: 0.41